https://doi.org/10.4081/ahr.2026.215
‘Scromiting’ and compulsive hot showering in cannabis users
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 4 September 2026
Published: 23 October 2026
‘Scromiting’ is the colloquial term for the simultaneous screaming and vomiting that characterizes the extraordinary intensity of pain experienced during acute hyperemetic episodes that occur in some long-term users of high doses of cannabinoids. It is recognized as a distinct clinical entity with a characteristic triad of features: prolonged history of daily or near-daily cannabis use, recurrent episodes of severe nausea and vomiting, and compulsive use of hot baths or showers, which patients have found to give temporary symptomatic relief. The intent of this review is to present a succinct overview of what (little) is known about postulated mechanisms, overlap with relationship to pain, and aspects of the clinical presentation.
Downloads
1.Loganathan P, Gajendran M, Goyal H. A comprehensive review and update on cannabis hyperemesis syndrome. Pharmaceuticals (Basel) 2024;17:1549. DOI: https://doi.org/10.3390/ph17111549
2.Pergolizzi JV, Jr., LeQuang JA, Bisney JF. Cannabinoid hyperemesis. Med Cannabis Cannabinoids 2019;1:73-95. DOI: https://doi.org/10.1159/000494992
3.Lake S, Murray CH, Henry B, et al. High-potency cannabis use and health: a systematic review of observational and experimental studies. Am J Psychiatry 2025;182:616-38. DOI: https://doi.org/10.1176/appi.ajp.20240269
4.Jiménez-Castillo RA, Arumugam S, Remes-Troche JM, Venkatesan T. Cannabinoid hyperemesis syndrome: A review. Rev Gastroenterol Mex (Engl Ed) 2025;90:214-26. DOI: https://doi.org/10.1016/j.rgmxen.2025.02.002
5.Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004;53:1566-70. DOI: https://doi.org/10.1136/gut.2003.036350
6.Warr D, Hesketh P. Cannabinoids as antiemetics: everything that's old is new again. Ann Oncol 2020;31:1425-6. DOI: https://doi.org/10.1016/j.annonc.2020.08.2104
7.Luther V, Yap L. A hot bath to calm what ails you: the Cannabis Hyperemesis Syndrome. Acute Med 2012;11:23-4. DOI: https://doi.org/10.52964/AMJA.0537
8.Zimmer DI, McCauley R, Konanki V, et al. Emergency department and radiological cost of delayed diagnosis of cannabinoid hyperemesis. J Addict 2019;2019:1307345. DOI: https://doi.org/10.1155/2019/1307345
9.Perisetti A, Gajendran M, Dasari CS, et al. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Ann Gastroenterol 2020;33:571-8. DOI: https://doi.org/10.20524/aog.2020.0528
10.Rubio-Tapia A, McCallum R, Camilleri M. AGA Clinical Practice update on diagnosis and management of cannabinoid hyperemesis syndrome: commentary. Gastroenterology 2024;166:930-4.e1. DOI: https://doi.org/10.1053/j.gastro.2024.01.040
11.Randall K, Hayward K. Emergent medical illnesses related to cannabis use. Mo Med 2019;116:226-8.
12.Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol (Phila) 2018;56:15-24. DOI: https://doi.org/10.1080/15563650.2017.1349910
13.Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment–a systematic review. J Med Toxicol 2017;13:71-87. DOI: https://doi.org/10.1007/s13181-016-0595-z
14.Klazura G, Geraghty JR, Rojnica M, et al. Cannabinoid hyperemesis syndrome complicated by pneumomediastinum: implications for pediatric surgeons. Clin Surg J 2022;5:6-13. DOI: https://doi.org/10.25083/2559.5555/7.2.14
15.Hernandez JM, Paty J, Price IM. Cannabinoid hyperemesis syndrome presentation to the emergency department: A two-year multicentre retrospective chart review in a major urban area. CJEM 2018;20:550-5. DOI: https://doi.org/10.1017/cem.2017.381
16.Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J 2011;104:659-64. DOI: https://doi.org/10.1097/SMJ.0b013e3182297d57
17.Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc 2009;84:76-8. DOI: https://doi.org/10.4065/84.1.76
18.Osagie E, Mirza O. Recurrent severe burns due to cannabinoid hyperemesis syndrome. Cureus 2023;15:e34552. DOI: https://doi.org/10.7759/cureus.34552
19.Glodosky NC, Okey SA, Watson TD, Hammond D. Cannabinoid hyperemesis syndrome prevalence and risk factors in the U.S․ Int J Drug Policy 2026;153:105307. DOI: https://doi.org/10.1016/j.drugpo.2026.105307
20.abboushe J, Rubin A, Liu H, Hoffman RS. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic Clin Pharmacol Toxicol 2018;122:660-2. DOI: https://doi.org/10.1111/bcpt.12962
21.ElSohly MA, Majumdar CG, Chandra S, Radwan MM. A 10-year trend in cannabis potency (2013-2022) in different geographical regions of the United States of America. Front Public Health 2024;12:1442522. DOI: https://doi.org/10.3389/fpubh.2024.1442522
22.Senderovich H, Waicus S. A case report on cannabinoid hyperemesis syndrome in palliative care: how good intentions can go wrong. Oncol Res Treat 2022;45:438-43. DOI: https://doi.org/10.1159/000524746
23.Cash MC, Cunnane K, Fan C, Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. PLoS One 2020;15:e0230167. DOI: https://doi.org/10.1371/journal.pone.0230167
24.Lonsdale H, Kimsey KM, Brown JM, et al. Pediatric Cannabinoid hyperemesis: a single institution 10-year case series. J Adolesc Health 2021;68:255-61. DOI: https://doi.org/10.1016/j.jadohealth.2020.09.024
25.Vivolo-Kantor AM, Liu S, Tanz LJ, et al. Trends in emergency department visits involving cannabis hyperemesis syndrome identified using a new diagnosis code — United States, January 2023-May 2026. MMWR Morb Mortal Wkly Rep 2026;75:391-6. DOI: https://doi.org/10.15585/mmwr.mm7530a2
26.Wenger T, Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 2002;66:301-7. DOI: https://doi.org/10.1054/plef.2001.0353
27.Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24. DOI: https://doi.org/10.1038/39807
28.Russo EB, Spooner C, May L, Leslie R, Whiteley VL. Cannabinoid hyperemesis syndrome survey and genomic investigation. Cannabis Cannabinoid Res 2022;7:336-44. DOI: https://doi.org/10.1089/can.2021.0046
29.Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011;4:241-9. DOI: https://doi.org/10.2174/1874473711104040241
30.Sabbineni M, Scott W, Punia K, et al. SAEM GRACE: Dopamine antagonists and topical capsaicin for cannabis hyperemesis syndrome in the emergency department: A systematic review of direct evidence. Acad Emerg Med 2024;31:493-503. DOI: https://doi.org/10.1111/acem.14770
31.Siegel RB, Motov SM, Marcolini EG. Droperidol use in the emergency department: a clinical review. J Emerg Med 2023;64:289-94. DOI: https://doi.org/10.1016/j.jemermed.2022.12.012
32.Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Ann Emerg Med 2021;77:613-9. DOI: https://doi.org/10.1016/j.annemergmed.2020.08.021
33.Chopra Q, Peyko V, Lee JA, et al. Droperidol plus diphenhydramine for symptom improvement in suspected cannabinoid hyperemesis syndrome: a prospective cohort study. Open Access Emerg Med 2024;16:267-73. DOI: https://doi.org/10.2147/OAEM.S473627
34.Borgundvaag B, Bellolio F, Miles I, et al. Guidelines for reasonable and appropriate care in the emergency department (GRACE-4): alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. Acad Emerg Med 2024;31:425-55. DOI: https://doi.org/10.1111/acem.14911
35.Aziz A, Waheed T, Oladunjoye O, Oladunjoye A, Hanif M, Latif F. Topical capsaicin for treating cannabinoid hyperemesis syndrome. Case Rep Gastrointest Med. 2020;2020:8868385. DOI: https://doi.org/10.1155/2020/8868385
36.Smith SA, Safwat MA, Piper BJ, Addison MA. Unraveling the enigma of cannabinoid hyperemesis syndrome: a narrative review of diagnosis and management. Cureus 2025;17:e90961. DOI: https://doi.org/10.7759/cureus.90961
CRediT authorship contribution
All authors contributed to the conception and design of the manuscript, the drafting of the article and revising it critically for important intellectual content; and/or for final approval of the version to be published; and all agree to be accountable for all aspects of the work.
Data Availability Statement
No new data were generated.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.